Amyris (AMRS) Downgraded by ValuEngine

Amyris (NASDAQ:AMRS) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Monday, April 2nd.

Several other brokerages have also commented on AMRS. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Amyris in a research note on Monday, April 2nd. Zacks Investment Research raised Amyris from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. Finally, B. Riley assumed coverage on Amyris in a research note on Thursday, January 25th. They set a “buy” rating and a $8.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $8.19.

How to Become a New Pot Stock Millionaire

AMRS stock traded up $0.17 during trading on Monday, hitting $6.62. The company had a trading volume of 896,469 shares, compared to its average volume of 572,734. Amyris has a 1-year low of $1.86 and a 1-year high of $9.75. The stock has a market capitalization of $308.02, a PE ratio of -2.20 and a beta of 0.12. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78.



Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.24). The business had revenue of $80.59 million during the quarter, compared to the consensus estimate of $68.14 million. The company’s quarterly revenue was up 262.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.09) earnings per share. analysts expect that Amyris will post -0.59 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Tanaka Capital Management Inc. raised its holdings in Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after acquiring an additional 221,295 shares during the last quarter. Compagnie Lombard Odier SCmA raised its holdings in Amyris by 60.0% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock valued at $390,000 after acquiring an additional 39,000 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in Amyris in the 4th quarter valued at $451,000. KBC Group NV increased its holdings in shares of Amyris by 228.4% during the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after buying an additional 41,834 shares during the last quarter. Finally, Creative Planning acquired a new stake in shares of Amyris during the 4th quarter worth $188,000. Institutional investors own 22.27% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Amyris (AMRS) Downgraded by ValuEngine” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/04/17/amyris-amrs-rating-lowered-to-hold-at-valuengine.html.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply